Pulmonary Hypertension | Pharmacor | G7 | 2014

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH has increased thanks to recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.

Login to access report

launch Related Market Assessment Reports